MRI changes in psoriatic dactylitis--extent of pathology, relationship to tenderness and correlation with clinical indices.
OBJECTIVE
To quantify the extent of inflammation in psoriatic dactylitis and to examine the relationship between clinical and magnetic resonance imaging (MRI) data in both tender and non-tender dactylitis.


METHODS
Seventeen patients with psoriatic dactylitis underwent clinical assessment for 6 months after change of treatment, usually to methotrexate. Measures of dactylitis included the Leeds Dactylitis Index, the assessment tool used in the Infliximab in Psoriatic Arthritis Clinical Trial (IMPACT), a simple count of tender dactlylitic digits and a count of all dactylitic digits, both tender and non-tender. MRI scans of the affected hand or foot were performed before and after treatment using a 1.5T Siemen's scanner pre- and post-contrast.


RESULTS
All patients improved clinically, as did their respective dactylitis scores and MRI images. The findings on MRI in both dactylitic and non-dactylitic digits were profound and widespread. The difference between tender and non-tender dactylitis was quantitative rather than qualitative. Synovitis and soft-tissue oedema were the most frequent abnormalities being present in 69% of tender dactylitic digits but bone oedema and flexor tenosynovitis were also frequently seen. Soft-tissue oedema was circumferential and enhancing and not limited to association with the flexor or extensor tendons. None of the clinical indices of dactylitis showed a close relationship to the extent of MRI abnormalities.


CONCLUSIONS
MRI images demonstrate widespread abnormalities in digits of people with psoriatic arthritis. Tender dactylitic digits have more abnormalities than other digits but the relationship between clinical and MRI scores is not strong.
Healy
P J
PJ
Academic Unit of Musculoskeletal Medicine, University of Leeds, 36 Clarendon Road, Leeds LS2 9NZ, UK.
Groves
C
C
Chandramohan
M
M
Helliwell
P S
PS
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D004487:Edema / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D005384:Finger Joint / Q000473:pathology*; D006801:Humans; D006930:Hyperalgesia / Q000473:pathology / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D010146:Pain / Q000473:pathology / Q000503:physiopathology; D012720:Severity of Illness Index; D013585:Synovitis / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D014033:Toe Joint / Q000473:pathology*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D008727:Methotrexate